- Home
- APM vs EDSA Comparison
APM vs EDSA Comparison
Compare APM & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- EDSA
- Stock Information
- Founded
- APM 2010
- EDSA 2015
- Country
- APM United Kingdom
- EDSA Canada
- Employees
- APM N/A
- EDSA N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- EDSA Health Care
- Exchange
- APM Nasdaq
- EDSA Nasdaq
- Market Cap
- APM 9.8M
- EDSA 11.0M
- IPO Year
- APM 2018
- EDSA N/A
- Fundamental
- Price
- APM $0.76
- EDSA $2.21
- Analyst Decision
- APM
- EDSA Strong Buy
- Analyst Count
- APM 0
- EDSA 1
- Target Price
- APM N/A
- EDSA $21.00
- AVG Volume (30 Days)
- APM 25.7K
- EDSA 49.4K
- Earning Date
- APM 12-20-2024
- EDSA 12-13-2024
- Dividend Yield
- APM N/A
- EDSA N/A
- EPS Growth
- APM N/A
- EDSA N/A
- EPS
- APM N/A
- EDSA N/A
- Revenue
- APM $431,378.00
- EDSA N/A
- Revenue This Year
- APM $157,729.10
- EDSA N/A
- Revenue Next Year
- APM N/A
- EDSA N/A
- P/E Ratio
- APM N/A
- EDSA N/A
- Revenue Growth
- APM N/A
- EDSA N/A
- 52 Week Low
- APM $1.09
- EDSA $2.11
- 52 Week High
- APM $17.49
- EDSA $6.46
- Technical
- Relative Strength Index (RSI)
- APM 16.33
- EDSA 22.56
- Support Level
- APM $1.21
- EDSA $2.11
- Resistance Level
- APM $1.37
- EDSA $2.44
- Average True Range (ATR)
- APM 0.11
- EDSA 0.25
- MACD
- APM -0.02
- EDSA -0.05
- Stochastic Oscillator
- APM 1.33
- EDSA 8.18
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.